Gilead Sciences (NASDAQ:GILD) has shown mixed performance, drawing attention with promising developments and strong Q3 performances but also experiencing some setbacks. The company demonstrated sustained success with their drug, Livdelzi (Seladelpar), throughout its management of Primary Biliary Cholangitis. They also saw a 4% surge in their stock following positive drug trials and promising obesity and weight loss treatments. Citigroup has initiated Gilead Sciences at a buy rating and despite some investor sell-off, many financial establishments have increased their holdings in the company. The company has posted strong HIV and Oncology sales, affirming an optimistic investor outlook and despite some downward stock movement, recent analyst upgrades have bolstered confidence. Gilead’s revenue soared 7% to $7.5B in Q3, and they have subsequently raised their guidance for 2024 on account of strong HIV growth. Gilead is showing promising signs of real momentum with their efforts to end HIV and has also signed royalty-free voluntary licensing agreements to increase access to Lenacapavir for HIV prevention in high-incidence, resource-limited countries. However, there have been concerns surrounding failed drug trials such as the withdrawal of its bladder cancer drug in the US.
Gilead Sciences GILD News Analytics from Thu, 09 May 2024 07:00:00 GMT to Sat, 16 Nov 2024 14:05:40 GMT -
Rating 3
- Innovation 2
- Information 7
- Rumor 4
